Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience

Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience

Abstract Introduction Diabetic macular oedema (DMO) remains a significant cause of sight loss in the UK. Despite macular laser and anti-VEGF agents, a large proportion of patients remain with persistent DMO. We present our results of using 0.19 mg fluocinolone acetonide (FAc) intravitreal implant in...

Full description

Bibliographic Details
Main Authors: James F. Young, Andrew Walkden, Amy Stone, Sajjad Mahmood
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-07-01
Series:Ophthalmology and Therapy
Subjects:
Diabetic macular oedema
Diabetic retinopathy
Fluocinolone acetonide implant
Iluvien
Online Access:http://link.springer.com/article/10.1007/s40123-019-0197-3

Internet

http://link.springer.com/article/10.1007/s40123-019-0197-3

Similar Items